Eradication therapy of Helicobacter pylori infection by standard proton pump inhibitor-based triple therapies (clarithromycin and amoxicillin) has been correlated with cure of peptic ulcer disease. On the other hand an increase in drug-resistant H. pylori has been reported to be a clinical problem. Thus, the aim of this study was to clarify the effect of rifampicin by susceptibility tests and in vitro inducement of drug resistance on H. pylori. In the in vivo study, anti-H. pylori IgG antibody and the [13C] urea breath test were used in a total 40 tuberculosis and atypical tuberculosis patients treated with rifampicin. The prevalence of H. pylori infection was low in the patients treated with rifampicin, and the eradication rate was 23.1%. The results of this study suggested that rifampicin eradicates H. pylori in tuberculosis and atypical tuberculosis patients treated with the drug.
|Number of pages||4|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 2000 Jan 1|
- Helicobacter pylori
ASJC Scopus subject areas
- Pharmacology (medical)